• 關於安成About Us
    • Company Profile
    • Management Team
    • Milestones
    • Plant & Quality
    • Join Us
    • Contact
  • Products
  • 研究與發展Research & Development
    • High Barrier Generics
  • 投資人關係
    • Shareholder Services
    • Corporate Governance
    • Unaudited Monthly Sales
    • Financial Report
    • Shareholder Contacts
  • 新聞發佈News & Media
    • News
    • Announcement

News

Announcement

Home > News & Media > News
Communication starts here.
2016.09
TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Androgel 1.62%
2015.09
TWi Pharmaceuticals Issues GDR and raised NT$ 2.83 Billion
2015.09
TWi Pharmaceuticals President & CEO Ms. Tina Guilder will resign from her current roles and Chairman Dr. Chih-Ming Chen will become interim President & CEO
2015.08
TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69
2015.08
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia
2015.07
TWi Pharmaceuticals Launches Generic MEGACE ES® After Favorable Decision In Patent Suit
2015.06
TWi Pharmaceuticals Receives US FDA Final Approval on Generic Guanfacine HCl ER Tablet
2015.05
TWi Pharmaceuticals Announced the promotion of R&D EVP Jianbo Xie as COO
2015.04
TWi Announces Settlement with Takeda on Dexilant® Litigation
2015.04
TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.

 

Pages:1 - 2 - 3 - 4 - 5« Pre · Next »

©Copyright 2013 安成國際藥業股份有限公司版權所有